Reserved area

Credentials and contents in the EryDel “RESERVED AREA” are strictly confidential and the access is authorized only for the medical staff operating the EDS in the ATTeST study. The Content of the “RESERVED AREA” should not be copied, distributed or reproduced in whole or in part, nor distributed to any third party if not for the  training purpose of authorized EDS Operators. The Content of the “RESERVED AREA” is only for medically trained staff.

I Agree

2018-10-15

EryDel appoints Ronan Gannon as Chief Commericial Officer

» Download Press Release


2018-06-04

EryDel-Orphan Technologies signing a licensing and supply agreement

» Download Press Release


2018-05-14

EryDel to present at the UBS Global Healthcare Confernce 2018

» Download Press Release


2018-04-24

EryDel Raises Euro 26.5 Million in Financing

» Download Press Release


2018-02-16

EryDel Appoints Guenter R Janhofer, MD, as Chief Medical Officer
Urbino, Italy – February 16, 2018 - EryDel SpA (www.erydel.com), a clinical stage biopharmaceutical company specialized in the development of drugs and diagnostics delivered through autologous red blood cells, today announced the appointment of Guenter Reinhold Janhofer, MD, to the position of Chief Medical Officer

» Download Press Release


2017-03-06

EryDel announced the initiation of the Ataxia Telangiectasia Trial with the EryDex System (ATTEST) study

» Download Press Release


2016-01-07

EryDel Consortium gains Euro 6 million Funding for development of EDS for the treatment of Ataxia Telangiectasia

» Download Press Release


2015-05-19

Long term benefit of erytrocyte-delivered dexamathasone in Ataxia Telangiectasia

» Download Press Release


2015-05-11

EryDel expands Series B financing to 29.5M

» Download Press Release


2014-02-20

Phase II results in Ataxia Telangiectasia published in Orphanet Journal of Rare Diseases

» Download Press Release


2013-09-17

EryDel selected as one of the top five candidates in 2013 EuropaBio Most Innovative EU Biotech SME Award

» Download Press Release


2013-09-05

Enzyme-loaded erythrocytes restore normal blood concentrations of Phenylalanine in a mouse model of Phenylketonuria (PKU)

» Download Press Release


2013-07-31

EryDel SpA Completes €15 Million Series B financing

» Download Press Release


2013-06-17

EryDel SpA Announces EMA Orphan Drug Designation for EryDex for the treatment of Ataxia Telangiectasia

» Download Press Release


2013-04-29

The Stainig procedures brochure, is now availables for downloading in the Documents section. 

» Download Press Release


2013-02-12

The Injectable Saline Adaptor for EryKit_01 Instruction For Use - all languages - is now available for downloading in the Documents section. 

» Download Press Release


2012-10-29


2012-07-30


2012-06-01


2012-02-29


2010-09-13

Where We Are

×